From: Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
Parameter ((Mean ± SD/ Q1,Median,Q3) or (#\%)) | Treatment strategy | |||
---|---|---|---|---|
Confirmed cases (9) | Home-based care (4) | Hospital admission (5) | ||
Age | 49.22 ± 7.94 [41–64] | 51.25 ± 9.63 [41–64] | 47.6 ± 7.02 [42–59] | |
P-value a: 0.530 b | ||||
 Sex | Male | 4 (44.4%) | 1 (25%) | 3 (60%) |
Female | 5 (55.6%) | 3 (75%) | 2 (40%) | |
Disease duration | 9.33 ± 5.31 [4–18] | 10.00 ± 6.32 [4–18] | 8.80 ± 5.06 [4–15] | |
P-value a: 0.760 b | ||||
 Walking disability | 1.78 ± 1.30 [1–5] | 2.00 ± 2.00 | 1.6 ± 0.54 | |
P-value a: 0.730 c | ||||
 Number of Rituximab injections so far | Once | 0 (0%) | 0 (0%) | 0 (0%) |
Twice | 3 (33.3%) | 2 (50%) | 1 (20%) | |
Thrice | 0 (0%) | 0 (0%) | 0 (0%) | |
>  4 doses | 6 (66.6%) | 2 (50%) | 4 (80%) | |
 Extended Interval Dosing | Positive | 2 (22.2%) | 2 (50%) | 1 (20%) |
Negative | 7 (77.7%) | 2 (50%) | 4 (80%) | |
 Comorbidity | Positive | 0 (0%) | 0 (0%) | 0 (0%) |
Negative | 9 (100%) | 4 (100%) | 5 (100%) | |
 Recent relapse | Positive | 0 (0%) | 0 (0%) | 0 (0%) |
Negative | 9 (100%) | 4 (100%) | 5 (100%) | |
 Corticosteroids consumption | positive | 1 (11.1%) | 1 (25%) | 0 (0%) |
Negative | 8 (88.8%) | 3 (75%) | 5 (100%) | |
 self-isolation | Positive | 6 (66.6%) | 3 (75%) | 3 (60%) |
Negative | 3 (33.3%) | 1 (25%) | 2 (40%) | |
 COVID-19 contact | Positive | 4 (44.4%) | 1 (25%) | 4 (80%) |
Negative | 5 (55.5%) | 3 (75%) | 1 (20%) | |
 Final outcome | Cured/Discharged | 7 (77.7%) | 4 (100%) | 3 (60%) |
Death | 2 (22.2%) | 0 (0%) | 2 (40%) | |
Incidence Rate | Mild to Moderate Condition | Serious Condition | Case Fatality Rate | |
3.4% | 44.4% | 11% | 22.2% |